BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26527781)

  • 1. Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
    Ji Y; Rankin C; Grunberg S; Sherrod AE; Ahmadi J; Townsend JJ; Feun LG; Fredericks RK; Russell CA; Kabbinavar FF; Stelzer KJ; Schott A; Verschraegen C
    J Clin Oncol; 2015 Dec; 33(34):4093-8. PubMed ID: 26527781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of antiprogestational therapy for meningiomas.
    Grunberg SM
    Hum Reprod; 1994 Jun; 9 Suppl 1():202-7. PubMed ID: 7962466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
    Grunberg SM; Weiss MH; Russell CA; Spitz IM; Ahmadi J; Sadun A; Sitruk-Ware R
    Cancer Invest; 2006 Dec; 24(8):727-33. PubMed ID: 17162554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multiple usages for antiprogestins].
    Heikinheimo O
    Duodecim; 1994; 110(10):1001-8. PubMed ID: 7588093
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.
    Grunberg SM; Weiss MH; Spitz IM; Ahmadi J; Sadun A; Russell CA; Lucci L; Stevenson LL
    J Neurosurg; 1991 Jun; 74(6):861-6. PubMed ID: 2033444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mifepristone (RU 486) treatment of meningiomas.
    Lamberts SW; Tanghe HL; Avezaat CJ; Braakman R; Wijngaarde R; Koper JW; de Jong H
    J Neurol Neurosurg Psychiatry; 1992 Jun; 55(6):486-90. PubMed ID: 1619417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mifepristone in the management of meningiomas: A systematic review of literature.
    Sharma R; Garg K; Katiyar V; Tandon V; Agarwal D; Singh M; Chandra SP; Suri A; Kale SS; Mahapatra AK
    Neurol India; 2019; 67(3):698-705. PubMed ID: 31347538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486).
    Touat M; Lombardi G; Farina P; Kalamarides M; Sanson M
    Acta Neurochir (Wien); 2014 Oct; 156(10):1831-5. PubMed ID: 25078073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for meningiomas.
    Kyritsis AP
    J Neurooncol; 1996 Sep; 29(3):269-72. PubMed ID: 8858533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo.
    Matsuda Y; Kawamoto K; Kiya K; Kurisu K; Sugiyama K; Uozumi T
    J Neurosurg; 1994 Mar; 80(3):527-34. PubMed ID: 8113866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma.
    Altinoz MA; Ozpinar A; Elmaci I
    Neurosurg Rev; 2019 Jun; 42(2):351-369. PubMed ID: 29453736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large endometrial polyp in a patient on long-term mifepristone therapy.
    Martineau PA; Levental M
    J Ultrasound Med; 2000 Jul; 19(7):487-9. PubMed ID: 10898303
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical applications of the antiprogestins.
    Kettel LM
    Clin Obstet Gynecol; 1995 Dec; 38(4):921-34. PubMed ID: 8616987
    [No Abstract]   [Full Text] [Related]  

  • 14. Mifepristone: antineoplastic studies.
    Sartor O; Figg WD
    Clin Obstet Gynecol; 1996 Jun; 39(2):498-505. PubMed ID: 8734014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients receiving long-term treatment with mifepristone.
    Spitz IM; Grunberg SM; Chabbert-Buffet N; Lindenberg T; Gelber H; Sitruk-Ware R
    Fertil Steril; 2005 Dec; 84(6):1719-26. PubMed ID: 16359971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hydroxyurea treatment for unresectable meningioma].
    Fuentes S; Chinot O; Dufour H; Paz-Paredes A; Métellus P; Barrie-Attarian M; Grisoli F
    Neurochirurgie; 2004 Sep; 50(4):461-7. PubMed ID: 15547484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for rare brain tumors veers from traditional tack.
    McBride G
    J Natl Cancer Inst; 1997 Jul; 89(13):912-3. PubMed ID: 9214668
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
    Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
    Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.